Find out more about the research we fund.
We fund innovative translational research aimed at understanding more about ovarian cancer. Translational research helps move researchers’ ideas from the lab to the hospital. Together, we’re targeting projects that will lead to more personalised, kinder and more effective treatments for people living with ovarian cancer – and ultimately a cure.
We have funded research across the UK since 2012. So far we have committed over £1.8 million in research funding.
Led by Professor Sadaf Ghaem-Maghami at Imperial College London, this three-year project seeks to understand more about genetic variation in high grade serous ovarian cancer.
Led by Professor Caroline Springer and Professor Iain Hagan, researchers at the University of Manchester will use innovative technology to explore new ways to tackle high-grade serous ovarian cancer through targeting specially selected proteins.
This project, led by Professor Charlie Gourley at the University of Edinburgh, has been a huge success and has moved forward our understanding of low grade serous ovarian cancer (LGSOC).
This project led by Professor James Brenton explored the immune response in the tumour microenvironment, and increased understanding of how natural killer cells recognise and kill tumour cells.
Led by Professor Richard Edmondson at the University of Manchester, this project developed a more personalised approach to treating ovarian cancer through a better understanding of the range and type of mutation that occur in DNA damage response pathway.
Led by Professor Iain McNeish at the University of Glasgow, this project looked at developing new treatments for ovarian clear cell carcinoma, a rare subtype of ovarian cancer.
The aim of the project led by Dr Agnieszka Michael at the University of Surrey was to assess whether elemental diet, is an acceptable form of nutrition in patients with inoperable bowel obstruction.
Dr Elizabeth Moore led this investigation into novel methods for the earlier and more precise detection of ovarian cancer.
Led by Dr Srinivasan Madhusudan at the University of Nottingham, this research project looked at how to improve the effectiveness of chemotherapy by including other drugs that make the cancer cells more susceptible to damage done by the chemotherapy.
With few treatment options for ovarian cancer, many women become resistant to one of the two key drugs used in chemotherapy. Professor Ahmed's team looked at how microtubules are involved in resistance to paclitaxel chemotherapy.
Led by Dr Marc Tischkowitz, the team wanted to see if a more streamlined model of genetic counselling alongside testing for BRCA1 and BRCA2 mutations was cost effective, feasible and acceptable to women.
Led by Dr Anne Lanceley, this was a large, international study that aimed to predict who would benefit from chemotherapy, to avoid unnecessary treatment.
Sign up to receive emails and keep up to date on all things Target Ovarian Cancer
Sign up
